- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
BioForce Nanosciences Holdings, Inc. (OTC BB: BFNH), a producer of integrated biological and mechanical systems for life science researchers at the micro and nano scales, today announced that the company has been added as a component of the Ludlow Biotech Index (www.ludlowcapital.com/indices/biotech/historic/)
"We are pleased to include BioForce Nanosciences in the Ludlow Biotech Index," stated Thomas J. Latino, PhD, head of equity research at Ludlow BioVentures, Inc. "BioForce's record revenue and gross profit for the fourth quarter ending December 31, 2007 indicates that it has a viable business model and is making significant progress in expanding the market for its Nano eNabler system. BioForce's earnings prove that the company has completed a successful transition from a early stage developmental company to one that is a commercial enterprise with a growing base of clients. Ludlow BioVentures believes BioForce will continue to expand the market for its platform product, the Nano eNabler system, and other products throughout 2008, and this makes BFNH an attractive addition to our index."
Kerry Frey, President and Chief Executive Officer of BioForce Nanosciences, said, "We are thrilled to have been added to the Ludlow Biotech Index as it adds to our growing credibility as a provider of integrated biological and mechanical systems at the micro and nano levels. Being part of an index that includes such biotech heavyweights as Affymetrix, Amgen, Biogen Idec, Genentech, Genzyme and Millennium Pharmaceuticals is a tribute to our engineers and to our developing salesforce, and I want to take this opportunity to thank them for their efforts. We expect this to be a harbinger of things to come in 2008."
About Ludlow Biotech Index
The Ludlow Biotech Index tracks a basket of top US traded biotechnology stocks. The index provides both institutional and individual investors a gauge for tracking the day-to-day performance of the biotechnology sector. The index is designed for investors who have a long-term bullish outlook on the biotech market. The Ludlow Biotech Index is owned and operated by Ludlow BioVentures, Inc., based in New York City. www.ludlowcapital.com/bioventures/
About BioForce Nanosciences Holdings, Inc.
BioForce Nanosciences creates products and solutions for the life sciences by integrating biological and mechanical systems at the micro and nano scales. BioForce’s flagship product, the Nano eNabler™ molecular printer, gives the Company and its customers a platform for development and discovery by printing tiny domains of biological materials on surfaces with nanometer spatial precision. BioForce technology is being used in areas such as biosensor functionalization; pattering and cell adhesion; and the printing of proteins to guide neural cell growth. For more information, visit www.bioforcenano.com or call 515-233-8333.
This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in BioForce Nanosciences' most recent filings with the Securities and Exchange Commission. BioForce Nanosciences' actual results could differ materially from such forward-looking statements. BioForce assumes no duty to update these statements at any future date.
For more information, please click here
BioForce Nanosciences, Inc.
1615 Golden Aspen Drive, Suite 101
Ames, IA 50010 USA
Copyright © BioForce Nanosciences Holdings, Inc.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Nanometrics Announces Upcoming Investor Events May 10th, 2016
Aspen Aerogels to Present at the 28th Annual ROTH Conference March 14th, 2016
Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016